These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain. Salonia A, Castagna G, Saccà A, Ferrari M, Capitanio U, Castiglione F, Rocchini L, Briganti A, Rigatti P, Montorsi F. J Sex Med; 2012 Oct; 9(10):2708-15. PubMed ID: 22897643 [Abstract] [Full Text] [Related]
4. Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated? Gallina A, Ferrari M, Suardi N, Capitanio U, Abdollah F, Tutolo M, Bianchi M, Saccà A, Salonia A, Rigatti P, Montorsi F, Briganti A. J Sex Med; 2012 Mar; 9(3):903-8. PubMed ID: 22240189 [Abstract] [Full Text] [Related]
5. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction. Fisher WA, Rosen RC, Eardley I, Niederberger C, Nadel A, Kaufman J, Sand M. J Sex Med; 2004 Sep; 1(2):150-60. PubMed ID: 16422969 [Abstract] [Full Text] [Related]
6. Sexual functioning mirrors overall men's health status, even irrespective of cardiovascular risk factors. Capogrosso P, Ventimiglia E, Boeri L, Capitanio U, Gandaglia G, Dehò F, Pederzoli F, Cazzaniga W, Scano R, Montorsi F, Salonia A. Andrology; 2017 Jan; 5(1):63-69. PubMed ID: 27989023 [Abstract] [Full Text] [Related]
7. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. Briganti A, Gallina A, Suardi N, Capitanio U, Tutolo M, Bianchi M, Passoni N, Salonia A, Colombo R, Di Girolamo V, Guazzoni G, Rigatti P, Montorsi F. J Sex Med; 2010 Jul; 7(7):2521-31. PubMed ID: 20487236 [Abstract] [Full Text] [Related]
8. Multiple PDE5Is use as a marker of decreased overall men's health: A real-life study. Oreggia D, Ventimiglia E, Capogrosso P, Boeri L, Cazzaniga W, Pederzoli F, Chierigo F, Dehò F, Montorsi F, Salonia A. PLoS One; 2018 Jul; 13(8):e0201601. PubMed ID: 30096166 [Abstract] [Full Text] [Related]
9. Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy. Briganti A, Di Trapani E, Abdollah F, Gallina A, Suardi N, Capitanio U, Tutolo M, Passoni N, Salonia A, DiGirolamo V, Colombo R, Guazzoni G, Rigatti P, Montorsi F. J Sex Med; 2012 Feb; 9(2):608-17. PubMed ID: 22189164 [Abstract] [Full Text] [Related]
10. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. Conaglen HM, Conaglen JV. J Sex Med; 2012 Mar; 9(3):857-65. PubMed ID: 22239731 [Abstract] [Full Text] [Related]
11. Erectile dysfunction (ED) is a shared sexual concern of couples II: association of female partner characteristics with male partner ED treatment seeking and phosphodiesterase type 5 inhibitor utilization. Fisher WA, Eardley I, McCabe M, Sand M. J Sex Med; 2009 Nov; 6(11):3111-24. PubMed ID: 19674250 [Abstract] [Full Text] [Related]
12. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. Montorsi F, Aversa A, Moncada I, Perimenis P, Porst H, Barker C, Shane MA, Sorsaburu S. J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928 [Abstract] [Full Text] [Related]
13. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Rosen RC, Allen KR, Ni X, Araujo AB. Eur Urol; 2011 Nov; 60(5):1010-6. PubMed ID: 21855209 [Abstract] [Full Text] [Related]
14. Salivary 8-OHdG: a useful biomarker for predicting severe ED and hypogonadism. Yasuda M, Ide H, Furuya K, Yoshii T, Nishio K, Saito K, Isotani S, Kamiyama Y, Muto S, Horie S. J Sex Med; 2008 Jun; 5(6):1482-91. PubMed ID: 18422497 [Abstract] [Full Text] [Related]
15. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction. El-Meliegy A, Rabah D, Al-Mitwalli K, Mostafa T, Hussein T, Istarabadi M, Lei Y, Gurbuz S. Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436 [Abstract] [Full Text] [Related]
16. SOP conservative (medical and mechanical) treatment of erectile dysfunction. Porst H, Burnett A, Brock G, Ghanem H, Giuliano F, Glina S, Hellstrom W, Martin-Morales A, Salonia A, Sharlip I, ISSM Standards Committee for Sexual Medicine. J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170 [Abstract] [Full Text] [Related]
17. Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. Porst H, Glina S, Ralph D, Zeigler H, Wong DG, Woodward B. J Sex Med; 2010 Oct; 7(10):3487-94. PubMed ID: 20584129 [Abstract] [Full Text] [Related]
18. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. Carvalheira AA, Pereira NM, Maroco J, Forjaz V. J Sex Med; 2012 Sep; 9(9):2361-9. PubMed ID: 22616766 [Abstract] [Full Text] [Related]
19. One patient out of four with newly diagnosed erectile dysfunction is a young man--worrisome picture from the everyday clinical practice. Capogrosso P, Colicchia M, Ventimiglia E, Castagna G, Clementi MC, Suardi N, Castiglione F, Briganti A, Cantiello F, Damiano R, Montorsi F, Salonia A. J Sex Med; 2013 Jul; 10(7):1833-41. PubMed ID: 23651423 [Abstract] [Full Text] [Related]
20. Men with mild erectile dysfunction benefit from sildenafil treatment. Bénard F, Carrier S, Lee JC, Talwar V, Defoy I. J Sex Med; 2010 Nov; 7(11):3725-35. PubMed ID: 20946161 [Abstract] [Full Text] [Related] Page: [Next] [New Search]